曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血浆BNP影响分析

摘要

Objective To study the trimetazidine with metoprolol BNP affect the clinical efficacy of coronary heart disease and heart failure plasma treatment. Methods A hospital in September 2014 - September 2015 period of 120 patients with CHD group and the control group trimetazidine treatment group were increased by metoprolol treatment, the two groups were observed before and after treatment and plasma BNP systolic blood pressure (SBP), left ventricular end-diastolic diam-eter (LVEDD), left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF). Results After treat-ment LVEDD (59.66 ± 2.71)mm, LVESD (40.81 ± 2.31) mm, LVEF (52.81 ± 5.21)%, respectively, higher than, P<0.05;LVEDD (51.92 ± 3.21)mm, LVESD (35.32 ± 2.61) mm, LVEF (59.45 ± 4.71)%, P<0.05; observation group after treatment of plasma BNP (265.52 ± 12.32) pg/ ml was significantly higher (227.12 ± 11.81) pg / ml, P<0.05. Conclusion Trimetazi-dine combined with metoprolol in patients with coronary heart disease helps reduce plasma BNP, improve heart function, and worthy of wider application.%目的：研究曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血浆BNP影响及临床疗效。方法选取该院2014年9月—2015年9月期间收治的120例冠心病患者进行随机分组各60例,对照组采用曲美他嗪治疗,对照组增加美托洛尔治疗,观察两组患者治疗前后血浆BNP及收缩压(SBP)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左室射血分数(LVEF)。结果观察组治疗后LVEDD (59.66±2.71)mm、LVESD (40.81±2.31)mm、LVEF (52.81±5.21)%分别高于对照组,差异有统计学意义P﹤0.05；LVEDD(51.92±3.21)mm、LVESD(35.32±2.61)mm、LVEF (59.45±4.71)%,,差异有统计学意义P﹤0.05；观察组治疗后血浆BNP(265.52±12.32)pg/mL明显高于对照组(227.12±11.81)pg/ml,差异有统计学意义,(P﹤0.05)。结论曲美他嗪联合美托洛尔对冠心病心力衰竭患者有利于降低血浆BNP、提高心功能,值得临床广泛与应用。